SynthesisFrontiers in pharmacology2025

Efficacy and safety of later-line targeted therapies in advanced non-small cell lung cancer with EGFR exon 20 insertion mutations: a systematic review.

Qiang Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.